40% off all research productsUse codeSOFTLAUNCHApply & shop →
NVO Health
Research cart Log In
Early human data Performance and Recovery

BPC-157

Also called Body Protection Compound 157; pentadecapeptide

An experimental 15-amino-acid peptide studied for tissue repair in lab and animal models. Small human reports exist, but they do not establish it as a treatment for injuries, gut disease or recovery.

Overview

What it is

A synthetic peptide linked to a protective compound described in gastric juice. Products sold under the name can differ in salt form and purity.

How it works

In rat tendon cells, it increased cell movement and survival under stress through FAK and paxillin signaling, without increasing cell multiplication. Animal studies report faster healing of gut, tendon, ligament and muscle injuries.

What the research shows

A 2021 chart review of 16 knee-pain patients reported less pain, but had no control group and mixed in thymosin beta-4. A small pilot in women with interstitial cystitis reported improvement after bladder instillation. A two-person IV safety pilot reported no adverse events. A phase 1 oral safety trial was registered (NCT02637284). FDA found the ulcerative colitis data inadequate.

Studied for

  • Tendon healingrats, lab
  • Knee painsmall retrospective report
  • Interstitial cystitissmall pilot
  • IV safetytwo people

Safety and regulatory status

Safety and side effects

No dependable side-effect rate exists. FDA's July 2026 briefing described reports of injection-site redness and swelling, shortness of breath requiring emergency care, and pigmentation changes with a mixed product. FDA also flags immune reactions and impurities. Seek urgent care for breathing difficulty after any injection.

Regulatory status

Not FDA approved. On FDA's compounding safety-risk list; reviewed by the advisory committee in July 2026, which is not approval. Prohibited at all times by WADA (S0).

Mixing and dosing reference

Reference information only. Read before using this section.
Reference information only. Not instructions. These mixing and dosing figures summarize published studies and third-party protocols so you can understand the research. They are not medical advice, not a recommendation that anyone use any substance, and not a treatment plan. They do not apply to Research Products, which are for laboratory research only and must never be used in humans or animals. Never self-administer any compound. Only a licensed healthcare professional who has evaluated you can decide whether a medication is appropriate and how it should be used.
Choose vial size
5 mg 10 mg 20 mg 40 mg

BPC-157 (10 mg Vial) Dosage Protocol

Vial
10 mg BPC-157
Add diluent
3 mL
Concentration
3.33 mg/mL
1 unit (U-100)
33.33 mcg in 0.01 mL
Route
Subcutaneous
Typical range
200–600 mcg once daily (gradual titration).

Standard / Gradual Approach

WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–2200 mcg (0.2 mg)6 units (0.06 mL)
Weeks 3–4400 mcg (0.4 mg)12 units (0.12 mL)
Weeks 5–8+600 mcg (0.6 mg)18 units (0.18 mL)

How to mix

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Administration technique
  • U-100 syringe units are volume markings: 100 units equals 1 mL, so one unit equals 0.01 mL. At 3.33 mg/mL, that one-unit mark contains about 33.3 mcg of BPC-157. It is not an international unit of peptide potency.
  • Use a new sterile syringe and needle for every injection and each separate vial entry.
  • Clean the vial stopper and selected skin site according to the governing laboratory or clinical procedure and allow the surface to dry.
  • Rotate subcutaneous sites rather than repeatedly using the same point.
  • Place used sharps directly into an appropriate puncture-resistant sharps container.
  • General injection technique does not validate the compound, the displayed amount, or the route. Institutional procedures and qualified oversight remain controlling.

Protocol source: PeptideDosages.com

Common questions

Does BPC-157 affect the liver or testosterone?

The research cannot establish either.

Is BPC-157 with TB-500 better?

No controlled study shows an advantage.

Does less pain mean the tissue healed?

No. Pain, function and structural repair are different outcomes.

Found in these blends

BPC-157 + TB-500 blendGLOW blendKLOW blendTri-Heal (TB-500 + BPC-157 + KPV blend)

Related in Performance and Recovery

AICARLarge human trials ARA-290Early human data BPC-157 + TB-500 blendUntested combination CartalaxEarly human data CJC-1295 (no DAC)Early human data CJC-1295 (with DAC)Early human data
Sources and further reading (7)
  1. FDA. BPC-157 bulk drug substances: briefing, July 2026.
  2. Chang CH, et al. BPC 157 and tendon healing: outgrowth, survival and migration. J Appl Physiol, 2011.
  3. Lee E, Padgett B. Intra-articular BPC 157 for knee pain. Altern Ther Health Med, 2021.
  4. Lee E, et al. BPC-157 in interstitial cystitis: pilot. Altern Ther Health Med, 2024.
  5. Lee E, Burgess K. Safety of IV BPC157 in humans: pilot. Altern Ther Health Med, 2025.
  6. WADA. 2026 Prohibited List, S0.
  7. Source summary: PeptideDosages.com research overview (rewritten for NVO).

Laboratory research material: BPC-157 Research Use Only

Educational information only. This content summarizes published research for general education. It is not medical advice, not a recommendation to use any substance, and not an instruction for human or animal use. It does not describe any Research Product sold on this site.